SB989, the “Wrongful Death Protection Act of 2025,” creates a new civil cause of action tied to abortion-inducing drugs. It defines abortion, abortion-inducing drugs, unborn child, fertilization, and related terms, and then imposes strict, joint-and-several civil liability on any person who manufactures, mails, distributes, transports, delivers, provides, or aids and abets the provision of abortion-inducing drugs when those drugs contribute to the death or injury of an unborn child or pregnant woman. The bill also sets a six-year limitations period, bars certain defenses, voids waivers of the right to sue, and includes specific exceptions for life-saving abortions, protected speech, federally protected conduct, and certain public services.
The bill is drafted to have broad reach beyond Oklahoma’s borders. It applies to abortions performed, induced, or attempted on Oklahoma residents regardless of where the conduct occurs, limits venue transfer, bars class actions, and attempts to extend personal jurisdiction to the maximum extent allowed by state and federal constitutions. It also includes provisions aimed at insulating the act from legal challenges by asserting sovereign, governmental, and official immunity for the state and its officers, restricting courts from issuing injunctions or declaratory relief against enforcement, and directing courts to apply an expansive severability rule so that any valid portion can survive even if other parts are struck down.
In terms of state law impact, SB989 would add new sections to Title 12 of the Oklahoma Statutes and create a new abortion-related wrongful death framework focused specifically on medication abortion. It would expand potential civil exposure for drug manufacturers, distributors, online platforms in limited circumstances, and others involved in the chain of distribution, while expressly excluding the pregnant woman herself and certain constitutionally protected or federally preempted conduct. The bill also references existing Oklahoma law on abortions performed to preserve the life of a pregnant woman and incorporates constitutional and preemption limitations throughout.
The general sentiment reflected by the bill’s introduction is strongly anti-abortion and enforcement-oriented, with no recorded committee debate or votes in the provided materials. The caption and text suggest an intent to create aggressive civil liability and to make the law difficult to enjoin or invalidate before enforcement. Because there are no transcripts or vote tallies, there is no documented bipartisan support or opposition in the supplied record, but the structure of the bill indicates it is designed to advance abortion restrictions and litigation against providers and distributors of abortion medication.
The main points of contention likely center on the bill’s broad liability standard, its extraterritorial application, and its attempts to limit constitutional defenses and judicial remedies. Potential critics would likely focus on due process, preemption, free speech, interstate commerce, and access-to-medication concerns, while supporters would likely emphasize fetal protection, civil accountability, and the bill’s stated exceptions for life-saving care and federally protected conduct. The bill’s inclusion of immunity and anti-injunction language also suggests anticipated litigation over whether the state can enforce these provisions as written.
SB989 would create new civil liability provisions in Title 12 for wrongful death and personal injury claims arising from abortion-inducing drugs, expanding potential defendants to include manufacturers, distributors, transporters, deliverers, providers, and aiders and abettors. It would also alter venue, limitations, immunity, severability, and jurisdiction rules for these claims, while attempting to apply the law extraterritorially to Oklahoma residents and to restrict class actions, venue transfers, and certain defenses. The bill would not change criminal law directly, but it would significantly affect civil litigation exposure for abortion medication-related conduct and related service providers.
The bill appears to be driven by a strong anti-abortion policy position and a desire to create robust enforcement tools, including broad civil liability and procedural protections for the statute itself. No committee transcript or vote history was provided, so there is no recorded debate to measure formal support or opposition. Based on the text alone, the measure is clearly intended to be aggressive and litigation-resistant, which suggests it would likely be controversial among abortion-rights advocates, healthcare providers, and civil liberties groups.
The most likely areas of contention are the bill’s expansive liability standard, its attempt to impose liability without traditional but-for or proximate causation, and its prohibition on several common defenses. Opponents would likely object to the extraterritorial reach, the restrictions on judicial review and injunctions, and the effort to limit constitutional challenges through immunity and severability provisions. Supporters would likely defend the bill as necessary to deter abortion drug distribution and to provide remedies for deaths or injuries allegedly caused by those drugs, while emphasizing the exceptions for life-saving care and federally protected conduct.